The VITAL process helped launch HeartFlow®, a revolutionary technology that helps doctors diagnose and treat heart blockages.
Real benefits for clinicians
“VITAL was instrumental because, originally, I thought I’d have to convince my administration to adopt HeartFlow®. For me, as one person, it might have been very challenging to make the case for it.
But to have the backing of VITAL and their support in the pilot made it much easier. VITAL gave us the perfect avenue to put this technology into practice.
Any time we can prevent unnecessary procedures, especially invasive procedures like heart catheterizations, that reduces risks for the patient. The associated health care savings also are a plus.”
Moneal Shah, MD – Clinical Lead
Allegheny Health Network Cardiologist
of angiograms avoided (6 months post intervention)
cost savings (6 months post intervention)2
adverse events from canceled angiograms2
Improved patient experiences
- 61% of patients avoided an invasive angiogram3
- Similar revascularization rates4
- Zero adverse clinical events among patients whose angiogram was canceled5
- 26% cost reduction compared to usual care testing for patients with suspected coronary artery disease6
A VITAL collaboration
Because of VITAL’s collaboration with HeartFlow, Inc. and Allegheny Health Network clinicians, doctors now can have sophisticated 3-D modeling tools at their fingertips. HeartFlow® analysis improves the patient experience because it allows them to avoid more invasive testing for blockages. And it’s been shown to significantly improve quality of life.1
HeartFlow® uses images from standard coronary CT angiograms (cCTAs) to create personalized digital 3-D models of each patient’s coronary arteries. Using advanced computer algorithms to solve millions of complex equations, the technology determines a “fractional flow reserve” for all the arteries, which assesses the impact of blockages on blood flow.
This information helps physicians decide the best treatment for each patient.
Successful collaboration led to changes to medical policy as of February 2018.